Matinas BioPharma Holdings Inc（MTNB）價格預測MTNBMatinas BioPharma Holdings Inc

Alphio's MTNB stock price prediction model matches the current Matinas BioPharma Holdings Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.20 (-0.63%). The 1-week path is $0.20 (+0.48%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Matinas BioPharma Holdings Inc is not a good buy right now due to its declining financial health and significant operational challenges. The current price is $0.20, and the company has reported a staggering year-to-date change of -67.74%. Additionally, the RSI is at 38.803, indicating that the stock is in a bearish trend. The company has also faced compliance challenges with the NYSE due to stockholders' equity falling below $4 million, which is a significant risk. Furthermore, the forward P/E ratio is 0, indicating no expected earnings growth, and the company has reported consistent losses, with a net income of -$4.27 million in Q3 2024. Overall, the combination of these factors suggests that now is not the right time to invest in this asset.

Matinas BioPharma Holdings Inc (MTNB) last closed at $0.2, gaining +0.00%. These facts feed the 1-day and 1-week MTNB price prediction above.